Results 41 to 50 of about 6,976 (185)

Case Report: Unlocking opportunities in HER2-targeted antibody-drug conjugates for bulky leptomeningeal metastatic breast cancer

Frontiers in Oncology
Leptomeningeal carcinomatosis (LC) is a severe complication of metastatic breast cancer (mBC), with rising incidence. The prognosis for patients with LC has been poor, with a median overall survival of approximately four months.
Alessandro Leal, Alessandro Leal, Douglas Kondziolka, Douglas Kondziolka, Donato Pacione, Donato Pacione, Stacy Antwi, Stacy Antwi, Sylvia Kurz, Nancy Lin, Sylvia Adams, Sylvia Adams   +11 more
doaj   +1 more source

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

Drugs - Real World Outcomes, 2023
Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA.
Afsaneh Barzi, Feng Lin, Jinlin Song, Clara Lam, Xiaoyu Nie, Ahmed Noman, Winghan J. Kwong   +6 more
doaj   +1 more source

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2‐Positive Cancers

Cancer Science, EarlyView.
Overexpression of ABC transporters, especially ABCG2 and ABCB1, mediates acquired resistance to T‐DXd in HER2‐positive cancers. Inhibition of these transporters restored T‐DXd efficacy, highlighting efflux‐mediated resistance as a potential therapeutic target. ABSTRACT Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer
Yuya Murase, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda, Shigeki Sato, Jun Kinoshita, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura, Yuichi Tambo, Takahiro Shimizu, Masafumi Horie, Daichi Maeda, Richard W. Wong, Kazuyoshi Hosomichi, Takafumi Kobayashi, Satoshi Watanabe, Kenta Yamamura, Noriyuki Ohkura, Miki Abo, Seiji Yano   +23 more
wiley   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

Breast Cancer Research, 2020
Background There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).
Alberto Ocaña, Eitan Amir, Atanasio Pandiella   +2 more
doaj   +1 more source

Evaluating distant recurrence‐free survival and location of metastasis in HER2+ breast cancer by ER status

International Journal of Cancer, Volume 158, Issue 5, Page 1184-1192, 1 March 2026.
What's New? The prognostic significance of the presence or absence of human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) in breast cancer is well‐established. However, the relationship of HER2 and ER with distant disease recurrence and metastasis location is less well understood.
Damien Kaukonen, Alexander Ploner, Erwei Zeng, Jenny Bergqvist, Kamila Czene   +4 more
wiley   +1 more source

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer

Cancer Medicine
Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg   +5 more
doaj   +1 more source

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

Advanced Science, Volume 13, Issue 7, 3 February 2026.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li, Zezhong Yu, Tao Pu, Yanling Wu, Gang Wang, Youhua Xie, Tianlei Ying, Zhenlin Yang, Yibing Shi   +8 more
wiley   +1 more source

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma [PDF]

ESMO Gastrointest Oncol
Aoki Y, Nakayama I, Komura Y, Wakabayashi M, Fukuoka S, Hara H, Shoji H, Furuta M, Minashi K, Sato A, Fuse N, Sakamoto N, Kuwata T, Shitara K.   +13 more
europepmc   +2 more sources

An Overview of Liquid Chromatography–Mass Spectrometry (LC–MS) Methods for the Quantification of Antibody‐Drug Conjugates

Biomedical Chromatography, Volume 40, Issue 2, February 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalization. In vivo, ADCs exist as intact molecules, naked antibodies, or released, unconjugated (linker‐)payload.
Pauline L. M. Buitelaar, Hilde Rosing, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema   +4 more
wiley   +1 more source